These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5108819)

  • 1. Urinary excretion of free catecholamines in Graves' disease.
    Bayliss RI; Edwards OM
    J Endocrinol; 1971 Jan; 49(1):167-73. PubMed ID: 5108819
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on urinary excretion of catecholamines in hyperthyroidism].
    Kimura T; Inoue K; Adachi T; Oikawa R; Katsumata A
    Nihon Naibunpi Gakkai Zasshi; 1969 Feb; 44(11):1222-31. PubMed ID: 4182360
    [No Abstract]   [Full Text] [Related]  

  • 3. [Urinary excretion of catecholamines in patients with Graves-Basedow disease and hyperactive nodular goiter before and after treatment with propranolol].
    Mieczkowska J
    Ann Univ Mariae Curie Sklodowska Med; 1983; 38():307-14. PubMed ID: 6600077
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of long-term antithyroid treatment of graves' disease in relation to iodine intake.
    Lumholtz IB; Poulsen DL; Siersbaek-Nielsen K; Friis T; Rogowski P; Kirkegaard C; Hansen JM
    Acta Endocrinol (Copenh); 1977 Mar; 84(3):538-41. PubMed ID: 576529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Excretion of catecholamines in the dynamics of the therapy of diffuse toxic goiter].
    Ugoleva SV
    Ter Arkh; 1967 Feb; 39(2):43-8. PubMed ID: 5632980
    [No Abstract]   [Full Text] [Related]  

  • 6. [Increased urinary excretion of neopterin in patients with Graves-Basedow disease].
    Schreiber V; Tomsová Z; Límanová Z; Jůzová Z
    Cas Lek Cesk; 1989 Jul; 128(28):883-4. PubMed ID: 2790883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thyroid function and catecholamines].
    Mornex R; Fitoussi R; Bernier E; Fournier G
    Actual Endocrinol (Paris); 1973; 13(0):175-82. PubMed ID: 4802083
    [No Abstract]   [Full Text] [Related]  

  • 8. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of propranolol and carbimazole as adjuncts to iodine-131 therapy of hyperthyroidism.
    Aro A; Huttunen JK; Lamberg BA; Pelkonen R; Ikkala E; Kuusisto A; Rissanen V; Salmi J; Tervonen S
    Acta Endocrinol (Copenh); 1981 Mar; 96(3):321-7. PubMed ID: 7211093
    [No Abstract]   [Full Text] [Related]  

  • 10. Cholestyramine as monotherapy for Graves' hyperthyroidism.
    Er C; Sule AA
    Singapore Med J; 2016 Nov; 57(11):644-645. PubMed ID: 27872940
    [No Abstract]   [Full Text] [Related]  

  • 11. [Relation between urinary catecholamine content and hyperactivity due to yin deficiency in patients with hyperthyroidism].
    Zhao WK
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 May; 13(5):284-5. PubMed ID: 8219680
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of adrenergic activity in Graves-Basedow disease and in nodular goiter].
    Sodolski W; Hanzlik J; Mieczkowska J; Stelmasiak T; Zelazowska A
    Wiad Lek; 1990 Feb 1-15; 43(3-4):96-100. PubMed ID: 2368399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [On preoperative and postoperative treatment of severe hyperthyroidism using propranolol].
    Höfer R; Keminger K; Kraupp O; Seidl H; Steinbereithner K
    Wien Med Wochenschr; 1969 Feb; 119(5):89-94. PubMed ID: 4182147
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of anaprilin on the indicators of central hemodynamics and excretion of catecholamines in patients with thyrotoxicosis].
    Ozerova MR; Levchenko TP
    Vrach Delo; 1976 Feb; (2):72-5. PubMed ID: 1266158
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful management of Graves' disease in a patient undergoing regular dialysis therapy.
    McKillop JH; Leung AC; Wilson R
    Arch Intern Med; 1985 Feb; 145(2):337-9. PubMed ID: 3838431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbimazole and the autoimmune response in Graves' disease.
    McGregor AM; Petersen MM; McLachlan SM; Rooke P; Smith BR; Hall R
    N Engl J Med; 1980 Aug; 303(6):302-7. PubMed ID: 6247656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The inhibition test of thyroid function with triiodothyronine in hyperthyroid patients under medical therapy: comparison of the values obtained from measures of "early" uptake and in the organic phase].
    Valentini F; Reschini E; Lodeserto A; Vivarelli S; Miedico D
    Folia Endocrinol; 1968 Aug; 21(4):396-403. PubMed ID: 4185869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.